Occurrence of Multiple, Extensive and Pan Drug-Resistant Pseudomonas aeruginosa and Carbapenemase Production from Presumptive Isolates Stored in a Biobank at Ethiopian Public Health Institute

Figures & data

Table 1 Antibiotic Susceptibility Pattern of P. aeruginosa at National Reference Laboratory Ethiopia, January 2017 to March 2021

Antimicrobial Category	Antibiotics	2017			2018			2019			2020			2021			Total
		N = 26			N=34			N=21			N=12			N=7			N=100
		S	I	R	S	I	R	S	I	R	S	I	R	S	I	R	%S	%I	%R
Aminoglycosides	Amikacin	26	0	0	34	0	0	20	1	0	11	0	1	6	0	1	97	1	2
	Gentamicin	25	0	1	31	2	1	19	0	2	11	0	1	5	0	2	91	2	7
Cephalosporins	Cefepime	21	0	5	25	0	9	12	0	9	7	0	5	4	0	3	69	0	31
	Ceftazidime	19	1	6	24	0	10	9	0	12	8	1	3	3	0	4	63	2	35
Fluoroquinolones	Ciprofloxacin	23	2	1	29	0	5	12	3	6	9	0	3	4	0	3	77	5	18
	Levofloxacin	22	1	3	23	3	8	11	3	7	9	0	3	4	0	3	69	7	24
Carbapenems	Imipenem	24	2	0	26	2	6	15	0	6	6	2	4	4	1	2	75	7	18
	Meropenem	26	0	0	27	4	3	15	0	6	8	1	3	5	1	1	81	6	13
Polymyxin B	Colistin	20	4	2	33	0	1	18	0	3	10	2	0	6	1	0	87	7	6
β-Lactam combinations	Ceftolozane-tazobactam	25	0	1	32	0	2	18	0	3	10	0	2	5	1	1	90	1	9
	Piperacillin-tazobactam	20	2	4	26	2	6	12	7	2	9	1	2	4	1	2	71	13	16

Abbreviations: S, sensitive; I, intermediate; R, Resistance.

Figure 1 Proportions of MDR, XDR, and PDR P. aeruginosa at national reference laboratory Ethiopia, January 2017 to March 2021.

Figure 2 Modified carbapenem inactivation method results for tested P. aeruginosa at national reference laboratory Ethiopia.